A 48-year-old female, known case of metastatic breast cancer, presents with disease progression despite prior therapy. Her tumor shows borderline HER2 expression (IHC 2+), and biomarker reports remain equivocal without definitive confirmation on further testing. Clinically, she is showing aggressive disease progression with increasing tumor burden and worsening symptoms, raising concern for the need for timely therapeutic intervention. Your Clinical Opinion Matters!
In this challenging case of HER2 equivocal metastatic breast cancer, every decision can impact patient outcomes. Would you wait for confirmatory reports, or initiate treatment based on disease progression? Share your reasoning in the comments Learn how fellow clinicians are approaching this dilemma Don’t just observe—be a part of the discussion and shape the conversation. Join the debate now!
